Castleman’s disease in the rheumatological practice
Schmalzing M, Sander O, Seidl M, et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024 Aug 22;83(3). doi:10.1007/s00393-024-01560-5
Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report
Jóri B, Bundschuh O, Falk M, Heukamp LC, Kluge A, Tiemann M, et al. Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report. Transl Lung Cancer Res 2024 Jul 30;13(7):1749-1755. doi:10.21037/tlcr-23-769. Epub 2024 Jul 15
Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
EGFR, non small cell lung cancer (NSCLC), tyrosine kinase inhibitor (TKI)
Christopoulos P, Herster F, Hoffknecht P, Falk M, Tiemann M, Kopp HG, et al. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report. Front Oncol 2024 May 06;14:1347742. doi: 10.3389/fonc.2024.1347742
Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis
Maslenkina K, Mikhaleva L, Mikhalev A, Kaibysheva V, Atiakshin D, Motilev E, et al. Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis. Biomedicines 2023 Dec 1;11(12):3204. doi: 10.3390/biomedicines11123204
Testing for deficient mismatch repair and microsatellite instability : A focused update
Immun-Checkpoint-Inhibition, Immune checkpoint inhibitors, Immunhistochemie, immunohistochemistry
Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker Edmonston T, Dietmaier W, et al. Testing for deficient mismatch repair and microsatellite instability : A focused update. Pathologie (Heidelb.) 2023 Nov;44(Suppl 2):61-70. doi:10.1007/s00292-023-01208-2. Epub 2023 Oct 24
Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract
Adenosquamöses Karzinom, Adenosquamous carcinoma, esophageal adenocarcinoma, gastric cancer, Immun-Checkpoint-Inhibition, Magenkarzinom, PD-L1
Baretton GB, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, et al. Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J Cancer Res Clin Oncol 2023 Nov;149(17):16231-16238. doi: 10.1007/s00432-023-05180-5. Epub 2023 Oct 24
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
hybrid capture-based next-generation sequencing (NGS), Osimertinib, Resistenz, Resistenzmutation
Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr Oncl 2023 Sep 27;30(10):8805-8814. doi:10.3390/curroncol30100635
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
disease monitoring, EGFR, hybrid capture-based next-generation sequencing (NGS), Liquid Biopsy, Osimertinib
Falk M, Schatz S, Reich FPM, Schmidt S, Galster M, Tiemann M, et al. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Curr. Oncol. 2023 Sep 28;30(10):8865-8871. doi:10.3390/curroncol30100640
Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets
metastasiert, metastatic, microbiome, Mikrobiom
Shakhpazyan N, Mikhaleva L, Bedzhanyan A, Giovea Z, Sadykhov N, Mikhalev A, et al. Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. Biomedicines 2023 Aug 23;11(9):2361. doi: 10.3390/biomedicines11092361
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
NOGGO GIS v1 Assay
Willing EM, Vollbrecht C, Vössing C, et al. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers 2023 Jun 30;15(13):3445. doi:10.3390/cancers15133445